Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

  • W. P. Yong, B. C. Goh, R. A. Soo, H. C. Toh, K. Ethirajulu, J. Wood, V. Novotny-Diermayr, S. C. Lee, W. L. Yeo, D. Chan, D. Lim, E. Seah, R. Lim, J. Zhu
  • Annals of Oncology, March 2011, Oxford University Press (OUP)
  • DOI: 10.1093/annonc/mdq784

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Dr veronica diermayr